CN101229128A - Cefepime hydrochloride powder injection and preparing method thereof - Google Patents
Cefepime hydrochloride powder injection and preparing method thereof Download PDFInfo
- Publication number
- CN101229128A CN101229128A CNA2008100011848A CN200810001184A CN101229128A CN 101229128 A CN101229128 A CN 101229128A CN A2008100011848 A CNA2008100011848 A CN A2008100011848A CN 200810001184 A CN200810001184 A CN 200810001184A CN 101229128 A CN101229128 A CN 101229128A
- Authority
- CN
- China
- Prior art keywords
- cefepime
- hydrochloride
- preparation
- cefepime hydrochloride
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention which discloses a hydrochloric acid cefepime powder injection consists of the raw material hydrochloric acid cefepime and supplemental material L-arginine and is characterized in that in the hydrochloric acid cefepime powder injection for injection, the content of the supplemental material L-arginine is 83.5 percent of the raw material hydrochloric acid cefepime; the hydrochloric acid cefepime powder injection provided by the invention is provided with a pH value about 4.5 and is good in stability.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, relate to a kind of cefepime hydrochloride powder injection and preparation method thereof specifically.
Background technology
Cefepime (Cefepim, BMY-28142, CFPM) be by Bu Mai-Shi Guibao company (Bristol-Myerssquibb) develop the 4th generation cephalosporin for injections, in 1993 in Sweden's Initial Public Offering, entered Chinese market in 1998.
Title: hydrochloride for injection cefepime (English name: Cefepime Hydrochloride for Injection)
Molecular formula: C
19H
25ClN
6O
5S
2HClH
2O
Molecular weight: 571.50
Chemical name: 1-[[(6R, 7R)-7-[2-(2-amino-4-thiazolyl)-glyoxyl amino]-2-carboxyl-8-oxo-5-thia-1-azabicyclo [4,2,0] oct-2-ene-3-yl] methyl]-1-crassitude chloride, 72-(Z)-(0-methyloxime) hydrochloric acid-hydrate
Chemical structural formula:
The hydrochloride for injection cefepime be the 4th generation cephalosporins.Compare with third generation cephalosporin, antimicrobial spectrum is wider, and antibacterial activity is stronger, and is more stable to bacteriogenic beta-lactamase.When keeping the third generation cephalosporin characteristic, enhancing is to G-bacterium antimicrbial power, because they contain a quaternary nitrogen positive charge on 3, can form amphion, and molecular structure is bullet-shaped, can passes the albumen bypass rapidly, make its adventitia transmitance improve 5-7 doubly, reduce significantly with the affinity of chromosome beta-lactamase such as enterobacter cloacae, improve enzyme stability, so enterobacter cloacae and bacillus pyocyaneus etc. is had stronger antibacterial activity.Because advantages such as this medical instrument has efficiently, low toxicity, wide spectrum are used determined curative effect, high safety clinically in a large number.
The pH value of this medicine raw material cefepime hydrochloride is about 1.6-2.1, be used for the pH value that human body must be adjusted this medicine.US5095011 discloses a kind of injection cefepime injectable powder, i.e. Maxipime (Maxipime) injectable powder, and by 375mg arginine and 4.45ml water for injection and 500mg cefepime hydrochloride mixed preparing, pH value is 3-7.
WO2006/106529 also discloses a kind of injection cefepime injectable powder, is made up of major ingredient and L-arginine and water, and pH value is 3-7.
People such as Chen Zhenyang, Zhou Xiang studies the prescription of hydrochloride for injection cefepime according to Maxipime injectable powder prescription, the arginic addition of L-is explored and studied, thereby determined that the arginic addition of L-in the hydrochloride for injection cefepime is (referring to " research of hydrochloride for injection cefepime prescription ", modern food and medicine magazine, 2006 the 16th the 1st phases of volume).By screening, draw in every 1g cefepime hydrochloride that to add the arginic optimum range of L-be 720-730mg, the pH value of this product can maintain between the 4.0-6.0 in this scope, and color and clarity all meet the requirement of American Pharmacopeia (26 editions).This report shows that its pH increases along with the increase of L-arginine content in the hydrochloride for injection cefepime, and when the arginic amount of adding L-was 750mg in appropriate hydrochloric acid cefepime (being equivalent to cefepime 1g), pH value was 7.01; During 800mg, pH value is 7.65; During 900mg, pH value is 8.40.And when the arginic amount of adding L-was 740mg in appropriate hydrochloric acid cefepime (being equivalent to cefepime 1g), its clarity is less than No. 1 turbidity, and was undesirable.
Above-mentioned studies show that, its pH of hydrochloride for injection cefepime increases along with the increase of L-arginine content, when the arginic addition of L-is when adding the arginic amount of L-greater than 730mg in every 1g cefepime, pH value is 6.10, clarity does not meet the requirement of hydrochloride for injection cefepime less than No. 1 turbidity.Therefore, the arginic addition of L-in the Maxipime injectable powder of import is generally and adds L-arginine 725mg in every 1g cefepime.The arginic addition of L-is also for adding L-arginine 725mg in the hydrochloride for injection cefepime that domestic Duo Jia pharmaceutical factory is produced according to Maxipime injectable powder prescription in every 1g cefepime.As seen, prior art generally believes that pH value, clarity were difficult to meet the requirements when the arginic amount of L-was greater than 800mg in every 1g cefepime in the hydrochloride for injection cefepime injectable powder.
In addition, " stability study of hydrochloride for injection cefepime " is (referring to the stability study of the hydrochloride for injection cefepime of Wang Haiyang etc., drug identification, 2005 the 14th the 12nd phases of volume) stability of hydrochloride for injection cefepime is studied, from this research, can see, commercially available hydrochloride for injection cefepime is in accelerated test, only time sampling check in 1 month, the content of its related substance is just greater than 1%, change more obvious, and investigate in the test keeping sample for a long time, the variation of its related substances also clearly, visible its stability and bad.
The inventor is surprised to find that in the process that arginic addition is explored and screened to L-when adding L-arginine 835mg in every 1g cefepime, but the pH value long term maintenance is about 4.5, through the accelerated test 6 months and the investigation 12 months that keeps sample for a long time, the content of related substance is less than 1%, stability is better, and its color, clarity, bacterial endotoxin all meet officinal regulation.Thereby, for the research of hydrochloride for injection cefepime provides new prescription.In view of this, special proposition the present invention.
Summary of the invention
The object of the present invention is to provide a kind of prescription new, the better hydrochloride for injection cefepime of stability.
For achieving the above object, a kind of hydrochloride for injection cefepime injectable powder provided by the present invention, form by raw material cefepime hydrochloride and adjuvant L-arginine, it is characterized in that: in the described hydrochloride for injection cefepime injectable powder, the arginic content of described adjuvant L-is 83.5% of raw material cefepime hydrochloride, and wherein the amount of cefepime hydrochloride is in cefepime.
Prior art shows, adding the arginic optimum range of L-in every 1g cefepime is 720-730mg, be that the arginic content of adjuvant L-is the 72-73% of raw material cefepime hydrochloride (in cefepime), the pH value of hydrochloride for injection cefepime can maintain between the 4.0-6.0 in this scope, and color and clarity all meet the requirement of American Pharmacopeia (26 editions).When the arginic addition of L-surpasses 730mg promptly greater than 73% the time, then pH value will exceed the scope of 4.0-6.0; And when the arginic amount of adding L-was 740mg in appropriate hydrochloric acid cefepime (being equivalent to cefepime 1g), its clarity is promptly less than No. 1 turbidity, and was undesirable.When the arginic addition of L-was between 800-900mg is during promptly at 80-90%, then pH value should be between 7.65-8.40.And in the hydrochloride for injection cefepime injectable powder of the present invention, the arginic content of adjuvant L-is 83.5% of raw material cefepime hydrochloride (in cefepime), and pH value is about 4.5.The inventor also has query to this, thereby has carried out a large amount of tests repeatedly understanding reason wherein, but has all obtained identical result.Though the inventor does not understand reason wherein so far as yet, but obtained better hydrochloride for injection cefepime injectable powder of better effects if, stability according to prescription provided by the present invention and preparation method, its color, clarity, bacterial endotoxin all meet officinal regulation.Thereby the present invention provides a kind of new prescription for the hydrochloride for injection cefepime.
In addition, from " stability study of hydrochloride for injection cefepime " (referring to the stability study of the hydrochloride for injection cefepime of Wang Haiyang etc., drug identification, 2005 the 14th the 12nd phases of volume) can see that commercially available hydrochloride for injection cefepime is in accelerated test in the literary composition, only time sampling check in 1 month, the content of its related substance is just greater than 1%, changes more obviously, and investigates in the test keeping sample for a long time, the variation of its related substances also clearly, as seen its stability is not fine.Among the present invention, by stable comparative test, the hydrochloride for injection cefepime that can see product of the present invention is through the accelerated test 6 months and the investigation 12 months that keeps sample for a long time, and the content of its related substance is just greater than 1%, pH value and content all do not have significant change, and as seen its stability is better than the commercially available prod.
Another object of the present invention is to provide a kind of preparation method of hydrochloride for injection cefepime injectable powder, described preparation method is that raw material cefepime hydrochloride and adjuvant L-arginine are directly mixed.
In the prior art, cefepime hydrochloride and L-be arginic to be mixed with two kinds of methods, and a kind of is that two materials are dissolved in together, and lyophilizing makes then; Another kind method is directly mixed getting.Because what dried frozen aquatic products obtained is unformed powder, and the trees of water of crystallization are restive, therefore, the present invention selects cefepime hydrochloride and the direct blended method of L-arginine are mixed with injectable powder.
Among the present invention, described preparation method is specially after the supplementary material pulverizing, sieving, and in prescription ratio mixing, packing after the assay was approved promptly.Among the present invention, the back remix of earlier supplementary material being pulverized, sieved can make supplementary material mix more evenly.
Above-mentioned sieves to crossing 80 mesh sieves.The purpose of screening is in order to obtain the material than uniform particle size.This all has an important meaning smoothly to drug quality and preparation production.Screening all has tangible influence to the flowability of degree of mixing, particle, filling, content uniformity etc. in unit operationss such as mixing, granulation, tabletting.The back remix of earlier former, adjuvant being pulverized, sieved among the present invention can make former, adjuvant be evenly distributed, and mixes more evenly.
In the above-mentioned preparation method, described pulverizing, sieve, mixing and packing all carry out in 100 grades of clean areas.
In the preparation method of the present invention, described supplementary material also comprises before pulverizing, sieving removes outer package, dedusting cleaning and wiping sterilization.
Preparation method provided by the present invention specifically comprises the steps:
1) supplementary material is removed outer package after, dedusting cleaning, the wiping sterilization, it is standby to enter sterilizing room;
2), 80 mesh sieves will be crossed behind cefepime hydrochloride and the L-arginine pulverize separately at 100 grades of clean areas;
3) take by weighing step 2 at 100 grades of clean areas) resulting cefepime hydrochloride and L-arginine, in the ratio mixing of prescription, survey content and be sub-packed in the glass tube vial after qualified, tamponade, to roll lid, lamp inspection, be up to the standards, labeling, packing are promptly.
The present invention provides a kind of new prescription for the hydrochloride for injection cefepime, and this prescription is formed rationally, and preparation technology is feasible.Compare according to the prepared hydrochloride for injection cefepime of the prescription of Maxipime with Maxipime injectable powder of the prior art or other, its pH value can maintain about 4.5 for a long time, color, clarity, bacterial endotoxin inspection are all up to specification, have good stability, through check, all in the quality standard limits, middle test agent carried out 18 months the lab scale sample through 36 months long term test, all in the quality standard limits, related substance can be controlled in below 1.0% every investigation index.
Description of drawings
Fig. 1 is the technological process of production figure of product hydrochloride for injection cefepime of the present invention.
The specific embodiment
Below be the specific embodiment of the present invention, described embodiment is in order to further describe the present invention, rather than restriction the present invention.
Embodiment 1
Prescription:
Cefepime hydrochloride (in cefepime) 500g
L-arginine 417.5g
Be distributed into 1000
Preparation technology:
(1) former, adjuvant is removed outer package after, the dedusting cleaning, the wiping sterilization, it is standby to enter sterilizing room;
(2), 80 mesh sieves will be crossed behind cefepime hydrochloride and the L-arginine pulverize separately at 100 grades of clean areas;
(3) take by weighing cefepime hydrochloride and L-arginine at 100 grades of clean areas, in the ratio mixing of prescription, survey content and be sub-packed in the glass tube vial after qualified, tamponade, roll lid, lamp inspection, be up to the standards, labeling, packing are promptly.
Embodiment 2
Prescription:
Cefepime hydrochloride (in cefepime) 1000g
L-arginine 835g
Be distributed into 1000
Preparation technology:
(1) former, adjuvant is removed outer package after, the dedusting cleaning, the wiping sterilization, it is standby to enter sterilizing room;
(2), 80 mesh sieves will be crossed behind cefepime hydrochloride and the L-arginine pulverize separately at 100 grades of clean areas;
(3) take by weighing cefepime hydrochloride and L-arginine at 100 grades of clean areas, in the ratio mixing of prescription, survey content and be sub-packed in the glass tube vial after qualified, tamponade, roll lid, lamp inspection, be up to the standards, labeling, packing are promptly.
Embodiment 3
Prescription:
Cefepime hydrochloride (in cefepime) 2000g
L-arginine 1670g
Be distributed into 1000
Preparation technology:
(1) former, adjuvant is removed outer package after, the dedusting cleaning, the wiping sterilization, it is standby to enter sterilizing room;
(2), 80 mesh sieves will be crossed behind cefepime hydrochloride and the L-arginine pulverize separately at 100 grades of clean areas;
(3) take by weighing cefepime hydrochloride and L-arginine at 100 grades of clean areas, in the ratio mixing of prescription, survey content and be sub-packed in the glass tube vial after qualified, tamponade, roll lid, lamp inspection, be up to the standards, labeling, packing are promptly.
Below by test the example and comparative example beneficial effect of the present invention is described.
The investigation of [test example 1] pH value, color and clarity
Get the prepared hydrochloride for injection cefepime injectable powder of 1 embodiment 2, add water by labelled amount and be mixed with per 1 milliliter of aqueous solution that contains cefepime 0.1g, investigate its pH value, color and clarity respectively.
PH value is measured: sample thief is measured (2000 editions two appendix VI H of Chinese Pharmacopoeia) pH value in accordance with the law.
Colour measurement: sample thief and yellow standard color solution (two appendix IX of Chinese Pharmacopoeia version in 2000 A, first method) are relatively.
Clarity is measured: sample thief compares with No. 1 turbidity standard (two appendix IX of Chinese Pharmacopoeia version in 2000 B) as showing muddy.
Result of the test such as following table 1:
Table 1
| PH value | Color (comparing) with yellow | Clarity |
| 4.53 | No. 4 | Clarification |
[test example 2] study on the stability
(1) influence factor's test
Get 1 embodiment, 2 prepared hydrochloride for injection cefepime injectable powder and carry out illumination (airtight vial, illumination 4000lx), high temperature (60 ℃), low temperature (4 ℃) test respectively, placed 10 days, in the 0th, 5, the every index of sampling and measuring in the time of 10 days.The results are shown in Table 2:
Table 2. influence factor result of the test
| Project | Time (d) | Outward appearance | PH value | Content (%) | Related substance (%) |
| Illumination | 0 5 10 | White powder white powder white powder | 4.53 4.57 4.55 | 99.6 100.54 99.5 | 0.93 0.86 0.76 |
| High temperature | 0 5 10 | White powder white powder white powder | 4.53 4.55 4.55 | 100.21 99.96 99.59 | 0.93 0.94 0.95 |
| Low temperature | 0 5 10 | White powder white powder white powder | 4.53 4.55 4.56 | 99.95 99.64 99.76 | 0.93 0.95 0.94 |
(2) accelerated test
With lot number be 070605,070606,070607 sample to place relative humidity (RH) be 75% thermostatic container, constant temperature was placed 6 months in 40 ℃ of baking ovens, took a sample respectively at the 0th, 1,2,3, during June, measured every index.Each batch sample character is white powder, odorless as a result, and sterility test is all qualified, and other indexs see Table 3.
Table 3. accelerated test is investigated the result
| Time (moon) | PH value | Content (%) | Related substance (%) | ||||||
| A | B | C | A | B | C | A | B | C | |
| 0 | 4.53 | 4.56 | 4.55 | 99.64 | 99.68 | 99.65 | 0.94 | 0.96 | 0.93 |
| 1 | 4.52 | 4.55 | 4.54 | 99.53 | 99.73 | 99.71 | 0.95 | 0.95 | 0.95 |
| 2 | 4.52 | 4.56 | 4.54 | 99.58 | 99.68 | 99.67 | 0.96 | 0.97 | 0.94 |
| 3 | 4.55 | 4.53 | 4.52 | 99.53 | 99.75 | 99.71 | 0.97 | 0.99 | 0.96 |
| 6 | 4.56 | 4.54 | 4.53 | 99.66 | 99.70 | 99.73 | 0.98 | 0.98 | 0.98 |
Annotate: A, B, C are respectively three batch samples of lot number 070605,070606,070607
(3) the room temperature investigation that keeps sample
With lot number is that 070605,070606,070607 sample room temperature is placed, and respectively at the 0th, 3,6,9, the December sampling, measures every index.Each batch sample character is white powder, odorless as a result, and sterility test is all qualified, and other indexs see Table 4.
The table 4. room temperature investigation result that keeps sample
| Time (moon) | PH value | Content (%) | Related substance (%) | ||||||
| A | B | C | A | B | C | A | B | C | |
| 0 | 4.53 | 4.56 | 4.55 | 99.63 | 99.67 | 99.64 | 0.95 | 0.94 | 0.92 |
| 1 | 4.51 | 4.55 | 4.54 | 99.53 | 99.72 | 99.70 | 0.94 | 0.93 | 0.94 |
| 2 | 4.52 | 4.57 | 4.54 | 99.59 | 99.69 | 99.68 | 0.96 | 0.96 | 0.93 |
| 3 | 4.55 | 4.53 | 4.52 | 99.54 | 99.76 | 99.72 | 0.96 | 0.98 | 0.97 |
| 6 | 4.57 | 4.55 | 4.53 | 99.67 | 99.71 | 99.74 | 0.97 | 0.97 | 0.96 |
The above results shows, the having good stability of product hydrochloride for injection cefepime of the present invention, and pH value can maintain about 4.5 for a long time, and content, related substance are all in the quality standard scope.
The stability of [comparative example 1] product of the present invention and commercially available hydrochloride for injection cefepime relatively
This test example has carried out accelerated test and has kept sample for a long time investigating test to product of the present invention and commercially available hydrochloride for injection cefepime, and purpose is stability is compared.
Accelerated test: with lot number is that to place relative humidity (RH) be 75% thermostatic container for 070605 product of the present invention and commercially available hydrochloride for injection cefepime, constant temperature was placed 6 months in 40 ℃ of baking ovens, take a sample respectively at the 0th, 1,2,3, during June, measure every index.Each batch sample character is white powder, odorless as a result, and sterility test is all qualified, and other indexs see Table 5.
Test for a long time keeps sample: with lot number is that 070605 product of the present invention and commercially available hydrochloride for injection cefepime are placed in room temperature, respectively at the 0th, 3,6,9, the December sampling, measures every index.Each batch sample character is white powder, odorless as a result, and sterility test is all qualified, and other indexs see Table 5.
Table 5. accelerated test and room temperature keep sample and investigate the test comparative result
| Project | Time (moon) | PH value | Content (%) | Related substance (%) | |||
| The present invention | Commercially available | The present invention | Commercially available | The present invention | Commercially available | ||
| Accelerated test | 0 | 4.53 | 4.75 | 99.63 | 99.40 | 0.95 | 0.98 |
| 1 | 4.51 | 4.72 | 99.53 | 99.02 | 0.94 | 1.01 | |
| 2 | 4.52 | 4.72 | 99.59 | 99.32 | 0.96 | 1.00 | |
| 3 | 4.55 | 4.74 | 99.54 | 99.24 | 0.96 | 1.04 | |
| 6 | 4.57 | 4.76 | 99.67 | 98.97 | 0.97 | 1.17 | |
| Investigation for a long time keeps sample | 0 | 4.53 | 4.75 | 99.63 | 99.40 | 0.95 | 1.06 |
| 3 | 4.55 | 4.78 | 99.54 | 100.30 | 0.96 | 0.87 | |
| 6 | 4.57 | 4.76 | 99.67 | 100.0 | 0.97 | 1.01 | |
| 9 | 4.56 | 4.76 | 99.65 | 99.97 | 0.97 | 1.07 | |
| 12 | 4.58 | 4.70 | 99.61 | 99.97 | 0.99 | 1.12 | |
As can be seen from the above table, the hydrochloride for injection cefepime of product of the present invention is through the accelerated test 6 months and the investigation 12 months that keeps sample for a long time, pH value, content and related substance all do not have significant change, and commercially available hydrochloride for injection cefepime is in accelerated test, only time sampling check in 1 month, the content of its related substance is just greater than 1%, its variation is more obvious, and in the investigation test that keeps sample for a long time, the variation of its related substances also clearly, as seen, the stability of product hydrochloride for injection cefepime of the present invention is better than the commercially available prod.
Claims (7)
1. cefepime hydrochloride powder injection, form by raw material cefepime hydrochloride and adjuvant L-arginine, it is characterized in that: in the described hydrochloride for injection cefepime injectable powder, the arginic content of described adjuvant L-is 83.5% of raw material cefepime hydrochloride, and wherein the amount of cefepime hydrochloride is in cefepime.
2. the preparation method of the described cefepime hydrochloride powder injection of claim 1, it is characterized in that: described preparation method is that raw material cefepime hydrochloride and adjuvant L-arginine are directly mixed.
3. the preparation method of cefepime hydrochloride powder injection according to claim 2 is characterized in that: described preparation method is for after pulverizing supplementary material, sieve, and in prescription ratio mixing, packing after the assay was approved promptly.
4. the preparation method of cefepime hydrochloride powder injection according to claim 3 is characterized in that: described sieving to crossing 80 mesh sieves.
5. the preparation method of cefepime hydrochloride powder injection according to claim 4 is characterized in that: described pulverizing, sieve, mixing and packing all carry out in 100 grades of clean areas.
6. preparation method according to claim 5 is characterized in that: described supplementary material also comprises before pulverizing, sieving removes outer package, dedusting cleaning and wiping sterilization.
7. preparation method according to claim 6 is characterized in that: described preparation method comprises the steps:
1) supplementary material is removed outer package after, dedusting cleaning, the wiping sterilization, it is standby to enter sterilizing room;
2), 80 mesh sieves will be crossed behind cefepime hydrochloride and the L-arginine pulverize separately at 100 grades of clean areas;
3) take by weighing step 2 at 100 grades of clean areas) resulting cefepime hydrochloride and L-arginine, in the ratio mixing of prescription, survey content and be sub-packed in the glass tube vial after qualified, tamponade, to roll lid, lamp inspection, be up to the standards, labeling, packing are promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2008100011848A CN100482231C (en) | 2007-08-14 | 2008-01-18 | Cefepime hydrochloride powder injection and preparing method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710016394 | 2007-08-14 | ||
| CN200710016394.X | 2007-08-14 | ||
| CNB2008100011848A CN100482231C (en) | 2007-08-14 | 2008-01-18 | Cefepime hydrochloride powder injection and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101229128A true CN101229128A (en) | 2008-07-30 |
| CN100482231C CN100482231C (en) | 2009-04-29 |
Family
ID=39896150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2008100011848A Active CN100482231C (en) | 2007-08-14 | 2008-01-18 | Cefepime hydrochloride powder injection and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100482231C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849912A (en) * | 2010-06-13 | 2010-10-06 | 山东罗欣药业股份有限公司 | Cefepime hydrochloride composition sterile powder for injection |
| CN101773507B (en) * | 2010-02-05 | 2011-11-09 | 王明 | Cefepime hydrochloride/arginine pharmaceutical composition suspension injection |
| CN101822679B (en) * | 2010-02-02 | 2012-05-30 | 邓学峰 | Cefepime hydrochloride combined medicament |
| CN102525934A (en) * | 2011-12-16 | 2012-07-04 | 苏州二叶制药有限公司 | Preparation process of cefepime hydrochloride for injecting |
| CN102743388A (en) * | 2012-05-15 | 2012-10-24 | 南京优科生物医药有限公司 | Composition used for inhibiting bacteria generating novel beta lactamase |
| CN102824304A (en) * | 2011-06-15 | 2012-12-19 | 悦康药业集团有限公司 | Cefepime hydrochloride composition for injection and its preparation method |
-
2008
- 2008-01-18 CN CNB2008100011848A patent/CN100482231C/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101822679B (en) * | 2010-02-02 | 2012-05-30 | 邓学峰 | Cefepime hydrochloride combined medicament |
| CN101773507B (en) * | 2010-02-05 | 2011-11-09 | 王明 | Cefepime hydrochloride/arginine pharmaceutical composition suspension injection |
| CN101849912A (en) * | 2010-06-13 | 2010-10-06 | 山东罗欣药业股份有限公司 | Cefepime hydrochloride composition sterile powder for injection |
| CN102824304A (en) * | 2011-06-15 | 2012-12-19 | 悦康药业集团有限公司 | Cefepime hydrochloride composition for injection and its preparation method |
| CN102824304B (en) * | 2011-06-15 | 2014-03-12 | 悦康药业集团有限公司 | Cefepime hydrochloride composition for injection and its preparation method |
| CN102525934A (en) * | 2011-12-16 | 2012-07-04 | 苏州二叶制药有限公司 | Preparation process of cefepime hydrochloride for injecting |
| CN102743388A (en) * | 2012-05-15 | 2012-10-24 | 南京优科生物医药有限公司 | Composition used for inhibiting bacteria generating novel beta lactamase |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100482231C (en) | 2009-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100482231C (en) | Cefepime hydrochloride powder injection and preparing method thereof | |
| CN104800221B (en) | Medicinal cefetamet pivoxil hydrochloride composition for treating sensitive bacteria infectious diseases | |
| CN101856356B (en) | Cefazedone sodium composition powder injection | |
| CN102525963B (en) | Netilmicin sulfate lyophiled powder injection and preparation method thereof | |
| CN101849912B (en) | Cefepime hydrochloride composition sterile powder for injection | |
| CN106265536B (en) | Bortezomib pharmaceutical composition and preparation method thereof | |
| CN104161732B (en) | Injection omeprazole sodium and its production and use | |
| CN101756897A (en) | Clindamycin hydrochloride injection and preparation method thereof | |
| CN102824304B (en) | Cefepime hydrochloride composition for injection and its preparation method | |
| CN102942576B (en) | New crystal form composition of cefminox sodium and preparation method thereof | |
| CN102247375B (en) | Cefotetan disodium for injection, and preparation method thereof | |
| CN102846570B (en) | Cefditoren pivoxil composition tablets and preparation method thereof | |
| Haile et al. | Evaluation of Grewia ferruginea Hochst ex A. Rich mucilage as suspending agent in metronidazole benzoate suspension | |
| CN102743390B (en) | cefepime hydrochloride medicine composition, powder-injection thereof and preparation method thereof | |
| CN110327284B (en) | Cefodizime sodium for injection and preparation method thereof | |
| CN103304604B (en) | Clindamycin phosphate compound and preparation method and pharmaceutical composition thereof | |
| CN109620804B (en) | Ceftriaxone sodium powder injection preparation for injection and preparation method thereof | |
| CN102824309B (en) | Cefmetazole sodium powder for injection and preparation method thereof | |
| CN105193736A (en) | Medicinal cefetamet pivoxil hydrochloride dry suspension for treating sensitive bacterial infection diseases | |
| CN112957332A (en) | Tedizolid phosphate for injection and quality standard thereof | |
| CN106310286B (en) | Tosufloxacin tosylate composition | |
| CN105456268B (en) | Compound medicament composition of piperacillin sodium and tazobactam sodium and preparation method thereof | |
| CN109730969A (en) | A kind of levofloxacin lactate dispersible tablet and preparation method thereof | |
| CN103393596A (en) | Metronidazole suspension and preparation method thereof | |
| CN108047253A (en) | A kind of Ceftriaxone Sodium crystal-form compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. Free format text: FORMER NAME: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Seven of 276017 Shandong province Linyi city Luozhuang District Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Address before: Seven of 276017 Shandong province Linyi city Luozhuang District Patentee before: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160728 Address after: Seven of 276017 Shandong province Linyi city Luozhuang District Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Patentee after: Luo Xin Biotechnology (Shanghai) Co., Ltd. Address before: Seven of 276017 Shandong province Linyi city Luozhuang District Patentee before: Shandong Luo Xin Pharmaceutical Group Plc |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee after: Luoxin Pharmaceutical (Shanghai) Co., Ltd. Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Address before: 276017 Luoqi Road, Luozhuang District, Linyi City, Shandong Province Co-patentee before: Luo Xin Biotechnology (Shanghai) Co., Ltd. Patentee before: Shandong Luo Xin Pharmaceutical Group Plc |